CSIMarket Company Name, Ticker, Customers, else..
 
Artiva Biotherapeutics Inc   (NASDAQ: ARTV)
 
Price: $8.0900 $0.26 3.321%
Day's High: $8.390000343322754 Week Perf: -5.93 %
Day's Low: $ 7.86 30 Day Perf: -25.98 %
Volume (M): 437,238 52 Wk High: $ 14.53
Volume (M$): $ 0 52 Wk Avg: $6.88
Open: $7.87 52 Wk Low: $2.52



 Market Capitalization (Millions $) 319
 Shares Outstanding (Millions) 39
 Employees 104
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -91
 Cash Flow (TTM) (Millions $) -9
 Capital Exp. (TTM) (Millions $) 3

Business Description


The company conducts product development and clinical trials, including ongoing trials for the product candidate AlloNK. It plans to submit Investigational New Drug applications to the FDA, seek regulatory approvals, carry out research and development, and commercialize its product candidates.


   Company Address: 5505 Morehouse Drive San Diego 92121 CA
   Company Phone Number: 267-4467   Stock Exchange / Ticker: NASDAQ ARTV


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
IBRX        14.13% 
SNTI        5.2% 
• View Complete Report
   



Clinical Study

Promising Advances in B-cell Non-Hodgkin Lymphoma Treatment Insights from Artiva Biotherapeutics’ ASGCT Presentatio...

Published Tue, Apr 29 2025 7:27 AM UTC

Artiva Biotherapeutics, Inc. is poised to make a significant impact in the fight against B-cell non-Hodgkin lymphoma (NHL) through its innovative therapy, AlloNK, combined with the monoclonal antibody rituximab. At the upcoming 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), Artiva plans to present longer-term Phase 1/2 data reaffirming the effi...
Announcement

Navigating Challenges Artiva Biotherapeutics Strategic Enhancements Amid Financial Headwinds

Published Tue, Nov 12 2024 9:06 PM UTC

Artiva Biotherapeutics Inc presents a compelling narrative as it reports its financial results for the third quarter of 2024. This report encapsulates the company s ongoing commitment to advancing innovative therapies, particularly in the realm of autoimmune diseases, whilst grappling with the financial realities of the biotechnology sector.In the 12 months leading up to the...
Stock Market Announcement

Artiva Biotherapeutics Raises $167.0 Million in Upsized IPO, Ushering in a New Era of Advanced Cell Therapy

Published Thu, Jul 18 2024 11:09 PM UTC

Artiva Biotherapeutics: Revolutionizing the Field of Cell Therapy
The highly anticipated initial public offering (IPO) of Artiva Biotherapeutics, a leading biotechnology company focused on developing innovative cellular immunotherapies, has recently been unveiled. With the IPO being priced at an upsized $167.0 million, this financial milestone signifies a significant mo...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 326.36
Price to Sales (Expected) -
Price to Book 0.92
PEG (TTM) -

Financial Strength Current
Quick Ratio 23.96
Working Capital Ratio 24.16
Leverage Ratio (MRQ) 0.06
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -3.31 $
Revenues (TTM) 0.02 $
Cash Flow (TTM) -
Cash 8.87 $
Book Value 8.82 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -873,279
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.